Revefenacin Completed Phase 3 Trials for Chronic Obstructive Pulmonary Disease, COPD, Low Peak Inspiratory Flow Rate / Low Peak Inspiratory Flow Rate (PIFR) / Chronic Obstructive Pulmonary Disease (COPD) Treatment

IndicationsStatusPurposePhase
CompletedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT03095456Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD
NCT03573817A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD
NCT02518139A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
NCT02512510Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)
NCT02459080Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)